Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies

Bibliography

• Smith IE, Arnedos M. The evolution of adjuvant endocrine therapy: developments since St Gallen 2005. Breast 2007;16(Suppl 2):S4-9
   PubMedGoogle Scholar
• Salmon WD Jr, Daughaday WH. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 1957;49:825-36
   PubMed Web of Science ®Google Scholar
• Ullrich A, Bell JR, Chen EY, Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 1985;313:756-61
   PubMed Web of Science ®Google Scholar
• Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915-28
   PubMed Web of Science ®Google Scholar
• Osborne R. Commercial interest waxes for IGF-1 blockers. Nat Biotechnol 2008;26:719-20
   PubMed Web of Science ®Google Scholar
• Haluska P, Shaw HM, Batzel GN, Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007;13:5834-40
   PubMed Web of Science ®Google Scholar
• Collett-Solberg PF, Cohen P. The role of the insulin-like growth factor binding proteins and the IGFBP proteases in modulating IGF action. Endocrinol Metab Clin North Am 1996;25:591-614
   PubMed Web of Science ®Google Scholar
• Daughaday WH, Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 1989;10:68-91
   PubMed Web of Science ®Google Scholar
• Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34
   PubMed Web of Science ®Google Scholar
• Kelley KM, Oh Y, Gargosky SE, Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol 1996;28:619-37
   PubMed Web of Science ®Google Scholar
• Krywicki RF, Yee D. The insulin-like growth factor family of ligands, receptors, and binding proteins. Breast Cancer Res Treat 1992;22:7-19
   PubMed Web of Science ®Google Scholar
• LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995;16:143-63
   PubMed Web of Science ®Google Scholar
• Oates AJ, Schumaker LM, Jenkins SB, The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene. Breast Cancer Res Treat 1998;47:269-81
   PubMed Web of Science ®Google Scholar
• Sara VR, Hall K. Insulin-like growth factors and their binding proteins. Physiol Rev 1990;70:591-614
   PubMed Web of Science ®Google Scholar
• Sepp-Lorenzino L. Structure and function of the insulin-like growth factor I receptor. Breast Cancer Res Treat 1998;47:235-53
   PubMed Web of Science ®Google Scholar
• Stewart CE, Rotwein P. Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Physiol Rev 1996;76:1005-26
   PubMed Web of Science ®Google Scholar
• Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000;92:1472-89
   PubMed Web of Science ®Google Scholar
• De Meyts P. Insulin and its receptor: structure, function and evolution. Bioessays 2004;26:1351-62
   PubMed Web of Science ®Google Scholar
• Steiner DF, Chan SJ, Welsh JM, Kwok SC. Structure and evolution of the insulin gene. Annu Rev Genet 1985;19:463-84
   PubMed Web of Science ®Google Scholar
• Nakae J, Kido Y, Accili D. Distinct and overlapping functions of insulin and IGF-I receptors. Endocr Rev 2001;22:818-35
   PubMed Web of Science ®Google Scholar
• De Meyts P, Whittaker J. Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov 2002;1:769-83
   PubMed Web of Science ®Google Scholar
• Dong MQ, Venable JD, Au N, Quantitative mass spectrometry identifies insulin signaling targets in C. elegans. Science 2007;317:660-3
   PubMed Web of Science ®Google Scholar
• Brogiolo W, Stocker H, Ikeya T, An evolutionarily conserved function of the Drosophila insulin receptor and insulin-like peptides in growth control. Curr Biol 2001;11:213-21
   PubMed Web of Science ®Google Scholar
• Ryan PD, Goss PE. The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist 2008;13:16-24
   PubMed Web of Science ®Google Scholar
• Belfiore A. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 2007;13:671-86
   PubMed Web of Science ®Google Scholar
• Macaulay VM. Insulin-like growth factors and cancer. Br J Cancer 1992;65:311-20
   PubMed Web of Science ®Google Scholar
• Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer 2003;107:873-7
   PubMed Web of Science ®Google Scholar
• Hankinson SE, Willett WC, Colditz GA, Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-6
   PubMed Web of Science ®Google Scholar
• Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002;23:824-54
   PubMed Web of Science ®Google Scholar
• McMullen JR, Shioi T, Huang WY, The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110alpha) pathway. J Biol Chem 2004;279:4782-93
   PubMed Web of Science ®Google Scholar
• Chan JM, Stampfer MJ, Giovannucci E, Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6
   PubMed Web of Science ®Google Scholar
• Yu H, Spitz MR, Mistry J, Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 1999;91:151-6
   PubMed Web of Science ®Google Scholar
• Ma J, Pollak MN, Giovannucci E, Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999;91:620-5
   PubMed Web of Science ®Google Scholar
• Neuenschwander S, Roberts CT Jr, LeRoith D. Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid. Endocrinology 1995;136:4298-303
   PubMed Web of Science ®Google Scholar
• Pietrzkowski Z, Mulholland G, Gomella L, Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res 1993;53:1102-6
   PubMed Web of Science ®Google Scholar
• LeRoith D, Baserga R, Helman L, Roberts CT Jr. Insulin-like growth factors and cancer. Ann Intern Med 1995;122:54-9
   PubMed Web of Science ®Google Scholar
• Jiang Y, Rom WN, Yie TA, Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-I receptor. Oncogene 1999;18:6071-7
   PubMed Web of Science ®Google Scholar
• McCutcheon IE, Flyvbjerg A, Hill H, Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg 2001;94:487-92
   PubMed Web of Science ®Google Scholar
• Divisova J, Kuiatse I, Lazard Z, The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat 2006;98:315-27
   PubMed Web of Science ®Google Scholar
• Pollak MN, Chapman JW, Pritchard KI, NCIC-CTG MA14 Trial: Tamoxifen (tam) vs. tam + octreotide (oct) for adjuvant treatment of stage I or II postmenopausal breast cancer. J Clin Oncol 2008;26:532
   Google Scholar
• Byrd JC, Devi GR, de Souza AT, Disruption of ligand binding to the insulin-like growth factor II/mannose 6-phosphate receptor by cancer-associated missense mutations. J Biol Chem 1999;274:24408-16
   PubMed Web of Science ®Google Scholar
• Sohda T, Yun K, Iwata K, Increased expression of insulin-like growth factor 2 in hepatocellular carcinoma is primarily regulated at the transcriptional level. Lab Invest 1996;75:307-11
   PubMed Web of Science ®Google Scholar
• Toretsky JA, Helman LJ. Involvement of IGF-II in human cancer. J Endocrinol 1996;149:367-72
   PubMed Web of Science ®Google Scholar
• Li X, Nong Z, Ekstrom C, Disrupted IGF2 promoter control by silencing of promoter P1 in human hepatocellular carcinoma. Cancer Res 1997;57:2048-54
   PubMed Web of Science ®Google Scholar
• Yuen JS, Macaulay VM. Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin Ther Targets 2008;12:589-603
   PubMed Web of Science ®Google Scholar
• Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007;28:20-47
   PubMed Web of Science ®Google Scholar
• Scotlandi K, Picci P. Targeting insulin-like growth factor 1 receptor in sarcomas. Curr Opin Oncol 2008;20:419-27
   PubMed Web of Science ®Google Scholar
• Dowling RJ, Zakikhani M, Fantus IG, Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007;67:10804-12
   PubMed Web of Science ®Google Scholar
• Zakikhani M, Dowling R, Fantus IG, Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66:10269-73
   PubMed Web of Science ®Google Scholar
• Letsch M, Schally AV, Busto R, Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. Proc Natl Acad Sci USA 2003;100:1250-5
   PubMed Web of Science ®Google Scholar
• Law JH, Habibi G, Hu K, Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008;68:10238-46
   PubMed Web of Science ®Google Scholar
• Popken GJ, Hodge RD, Ye P, In vivo effects of insulin-like growth factor-I (IGF-I) on prenatal and early postnatal development of the central nervous system. Eur J Neurosci 2004;19:2056-68
   PubMed Web of Science ®Google Scholar
• Zhang H, Pelzer AM, Kiang DT, Yee D. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res 2007;67:391-7
   PubMed Web of Science ®Google Scholar
• Hewish M, Chau I, Cunningham D. Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat Anticancer Drug Discov 2009;4:54-72
   PubMed Web of Science ®Google Scholar
• Moreau P, Hulin C, Facon T, Phase I Study of AVE1642 Anti IGF-1R monoclonal antibody in patients with advanced multiple myeloma. ASH Annual Meeting Abstracts 2007;110:1166
   Google Scholar
• Tolcher AW, Patnaik A, Till E, A phase I study of AVE1642, a humanized monoclonal antibody IGF-1R (insulin like growth factor1 receptor) antagonist, in patients(pts) with advanced solid tumor(ST). J Clin Oncol 2008;26:3582
   PubMedGoogle Scholar
• Rothenberg ML, Poplin E, LoRusso P, Pharmacokinetic (PK) and pharmacodynamic (PD) results of Phase I studies of IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid malignancies. In: 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; 2008 Oct 21-24; Pergamon-Elsevier Science Ltd, Geneva, Switzerland; 2008, p. 174-5
   Google Scholar
• Higano C, LoRusso P, Gordon M, A phase I study of the recombinant human IgG1 anti-IGF-IR monoclonal antibody (Mab) IMC-A12, administered on a weekly basis to patients with advanced solid tumors: interim analysis. Mol Cancer Ther 2007;6:3439S-S
   Web of Science ®Google Scholar
• Hidalgo M, Tirado Gomez M, Lewis N, A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule. ASCO Meeting Abstracts 2008;26:3520
   Google Scholar
• Atzori F, Tabernero J, Cervantes A, A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors. J Clin Oncol 2008;26:3519
   Google Scholar
• Leong S, Gore L, Benjamin R, A phase I study of R1507, a human monoclonal antibody lGF1R (insulin-like growth factor receptor) antagonist given weekly in patients with advanced solid tumors. Mol Cancer Ther 2007;6:3360S-S
   Web of Science ®Google Scholar
• Rodon J, Patnaik A, Stein M, A phase I study of q3W R1507, a human monoclonal antibody IGF-1R (insulin-like growth factor receptor) antagonist in patients with advanced solid tumors. Mol Cancer Ther 2007;6:3360S-S
   Web of Science ®Google Scholar
• Yang XD, Jia XC, Corvalan JR, Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999;59:1236-43
   PubMed Web of Science ®Google Scholar
• Cohen BD, Baker DA, Soderstrom C, Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 2005;11:2063-73
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Alsina M, Fonseca R, Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol 2008;26:3196-203
   PubMed Web of Science ®Google Scholar
• Olmos D, Postel-Vinay S, Molife LR, Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 2010;11:129-35
   PubMed Web of Science ®Google Scholar
• Haluska P, Worden F, Olmos D, Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol 2010;65:765-73
   PubMed Web of Science ®Google Scholar
• Delattre O, Zucman J, Plougastel B, Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992;359:162-5
   PubMed Web of Science ®Google Scholar
• Prieur A, Tirode F, Cohen P, Delattre O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 2004;24:7275-83
   PubMed Web of Science ®Google Scholar
• Scotlandi K, Benini S, Sarti M, Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res 1996;56:4570-4
   PubMed Web of Science ®Google Scholar
• Tap WD, Demetri GD, Barnette P, AMG 479 in relapsed or refractory Ewing's family tumors (EFT) or desmoplastic small round cell tumors (DSRCT): Phase II results. J Clin Oncol 2010;28(15s):abstract 10001
   Google Scholar
• Pappo AS, Patel S, Crowley J, Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients (pts) with recurrent or refractory Ewing's sarcoma family of tumors (ESFT): results of a phase II SARC study. J Clin Oncol 2010;28(15s):abstract 10000
   Google Scholar
• Molife LR, Fong PC, Paccagnella L, The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Br J Cancer 2010;103:332-9
   PubMed Web of Science ®Google Scholar
• Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 2009;28:3009-21
   PubMed Web of Science ®Google Scholar
• de Bono JS, Attard G, Adjei A, Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res 2007;13:3611-16
   PubMed Web of Science ®Google Scholar
• Karp DD, Pollak MN, Cohen RB, Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin. J Thorac Oncol 2009;4:1397-403
   PubMed Web of Science ®Google Scholar
• Karp DD, Paz-Ares LG, Novello S, Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009;27:2516-22
   PubMed Web of Science ®Google Scholar
• de Bono JS, Attard G, Adjei A, Activity of the anti-IGF-IR antibody CP-751,871 in combination with docetaxel as first-line treatment for castration resistant prostate cancer in a randomized phase II trial. Molecular Targets and Cancer Therapeutics Congress, 21–24 October 2008, Geneva, Switzerland
   Google Scholar
• Ryan PD, Neven P, Dirix LY, Safety of the anti-IGF-1R antibody CP-751,871 in combination with exemestane in patients with advanced breast cancer. 31st Annual San Antonio Breast Cancer Meeting, 10–14 December 2008. San Antonio, USA
   Google Scholar
• Jassem J, Langer CJ, Karp DD, Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28(15s):abstract 7500
   Google Scholar
• Gualberto A, Dolled-Filhart M, Gustavson M, Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition. Clin Cancer Res 2010;16:4654-65
   PubMed Web of Science ®Google Scholar
• Gualberto A, Hixon ML, Karp DD, Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer 2011;104:68-74
   PubMed Web of Science ®Google Scholar
• Olmos D, Postel-Vinay S, Molife LR, Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 2009;11:129-35
   PubMed Web of Science ®Google Scholar
• Juergens H, Daw NC, Oberlin O, Safety and efficacy results from a phase 1/2 study of the anti-IGF-1R antibody figitumumab in patients with refractory Ewing's and other sarcomas. Ann Oncol 2010;21:p 408
   Web of Science ®Google Scholar
• Olmos D, Basu B, de Bono JS. Targeting insulin-like growth factor signaling: rational combination strategies. Mol Cancer Ther 2010;9:2447-9
   PubMed Web of Science ®Google Scholar
• Subbiah V, Naing A, Brown RE, Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures. PLoS One 2011;6:e18424
   PubMed Web of Science ®Google Scholar
• Quek R, Wang Q, Morgan JA, Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res 2011;17:871-9
   PubMed Web of Science ®Google Scholar
• Di Cosimo S, Bendell JC, Cervantes-Ruiperez A, A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors. J Clin Oncol 2010;28(15s):abstract 3008
   Google Scholar